chenodeoxycholic acid has been researched along with Diabetic Glomerulosclerosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adorini, L; D'Agati, V; Dobrinskikh, E; Dvornikov, A; Field, A; Garcia, G; Gonzalez, FJ; Gratton, E; Henriksen, K; Herman-Edelstein, M; Hill, A; Jiang, T; Kopp, JB; Krausz, KW; Levi, J; Levi, M; Lucia, S; Luo, Y; Myakala, K; Orlicky, D; Peng, Y; Pruzanski, M; Qiu, L; Ranjit, S; Rosenberg, AZ; Wang, D; Wang, XX; Xie, C | 1 |
1 other study(ies) available for chenodeoxycholic acid and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
Topics: Albuminuria; Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol; Cholic Acids; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Endoplasmic Reticulum Stress; Fibrosis; Glomerular Mesangium; Humans; Kidney Tubules; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mitochondria; Obesity; Oxidative Stress; Podocytes; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Triglycerides | 2018 |